Konrad
Morzkowski

Konrad Morzkowski runs a company most people will only meet by accident, on the day a doctor sticks a small wireless patch on their chest and tells them to go live their normal life for a week. The patch is called eWave. It has six leads. It talks to a smartphone over Bluetooth. It is FDA 510(k) cleared. And it represents an unsentimental answer to a question cardiology has been quietly avoiding for forty years: why does the standard ambulatory heart monitor still look like something engineered during the Carter administration.

Morzkowski is the co-founder and CEO of WearLinq, a San Francisco medtech company whose flagship device replaces the legacy Holter monitor with a continuous, multi-lead wearable that delivers clinician-grade ECG data to a phone in your pocket. He is 30-something, Swedish, Stanford-trained, and listed on the Forbes 30 Under 30 in Healthcare for 2024. He runs a team of roughly 39 people. He is not flamboyant. He is, by his own admission, a methodical filterer of advice.

Which is the polite way of saying he is stubborn.

The story he tells about how WearLinq came to exist sounds almost accidental until you look more closely. He arrived at Stanford in 2018 to do an MS in engineering with a plan to build AI applications for healthcare. He left Stanford in 2020 with co-founders he had met inside the classroom and a different problem on his hands - the problem that intelligence without input is theatre, and that the input layer for cardiology, the sensors, the patches, the workflows, was not anywhere near good enough to make the AI worth doing. So he and his collaborators decided to build the sensor first. Software people rarely make that choice. Morzkowski did.

WearLinq's product, eWave, is described by the company as the first wireless, continuous, FDA-cleared 6-lead ECG multimodal monitor. The six leads matter. A traditional patch monitor offers one or two leads, which is to a cardiologist what a postcard is to a portrait. Six leads gets you a multi-dimensional view of the heart. Continuous wear gets you data the patient didn't know they were generating. Wireless gets you a workflow that doesn't depend on couriering a black box back to a clinic. Stack the three together and you have not just a better monitor but a different category of monitoring.

This is the kind of detail that does not fit on a slide. Morzkowski has spent four years explaining it anyway, to VCs, to clinicians, to the FDA, and to the SBIR program that wouldn't fund him because his co-founders weren't US citizens.

The Morzkowski story does not begin with a teenager taking apart electronics in his bedroom in suburban Sweden, mostly because we have no public record that he did. What's verifiable is that he took an engineering degree at Chalmers University of Technology in Gothenburg - one of Scandinavia's stricter engineering schools - and then in 2018 he crossed an ocean to do a Master's at Stanford with the intention of using software to fix something in healthcare.

The pivot from software-for-healthcare to hardware-for-healthcare is the move most founders never make. It usually goes the other way. Hardware is slower, more capital-intensive, less forgiving of mistakes, and harder to demo over a Zoom call. Konrad made it because he met the right scientists at the right moment in a Stanford classroom, looked at the legacy of ambulatory cardiac monitoring, and decided the sensor layer was where the leverage was. Software can wait. Patches with electrodes cannot.

The early WearLinq years were the kind of grind that does not feature in keynote talks. The company applied for SBIR funding - the federal program that throws small grants at scientifically meritorious startups - and was disqualified because the team's makeup did not satisfy US citizenship requirements. That closed off the obvious dilution-free path to early capital. So Morzkowski did the unglamorous thing and started cold-emailing investors. Roughly 90% of the company's early money came in via outreach, not warm intros - an unusual ratio for a founder with a Stanford pedigree.

It worked. SpringTide Ventures led the seed, joined by Berkeley Catalyst Fund and Amino Capital. Smartlink Partners came in from Poland. The eWave patch cleared the FDA's 510(k) pathway. In May 2024 the company bought AMI Cardiac Monitoring, a 33-year-old monitoring lab, to give WearLinq its own Independent Diagnostic Testing Facility so it could bill payers directly across all 50 states and own the workflow that surrounds the device, not just the device itself. In December 2025, AIX Ventures led a $14M Series A.

The pattern across those moves is consistent: stack de-risking events one on top of the other, then go ask for more money. Morzkowski talks about this explicitly. He has called it a moat-building exercise. Most founders treat regulatory and reimbursement work as a cost. He treats it as a wall.